Q1’18 HIGHLIGHTS AND FINANCIALS

MAY 30TH, 2018

TONE KVÅLE, CFO & INTERIM CEO

LISA ROJKJAER, CMO

Nordic Nanovector ASA
Kjelsåsveien 168 B, 0884 Oslo, Norway
www.nordicnanovector.com
IR contact: IR@nordicnanovector.com

Forward-looking statements

This announcement contains certain forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector's business, financial condition and results of operations. The terms "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "targets", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statement. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in these forward-looking statements. Factors that could cause these differences include, but are not limited to, risks associated with implementation of Nordic Nanovector's strategy, risks and uncertainties associated with the development and/or approval of Nordic Nanovector's product candidates, ongoing and future clinical trials and expected trial results, the ability to commercialise Betalutin®, technology changes and new products in Nordic Nanovector's potential market and industry, Nordic Nanovector's freedom to operate (competitors patents) in respect of the products it develops, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions, and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Nordic Nanovector at a glance

Focused on the development of targeted therapies for haematological cancers

Lead candidate Betalutin® for treating NHL

- Novel anti-CD37 therapy in pivotal Phase 2b trial (PARADIGME) in 3L R/R FL – read-out expected 1H 2020
- Promising efficacy with encouraging duration of response and favourable safety profile seen in earlier trials
- Potential for Betalutin® in other NHL indications

Clear plan to bring Betalutin® to market

- Designed to enhance chances of Betalutin® gaining regulatory approval with a competitive product profile
- Intent to independently commercialise Betalutin® in major markets

Listed on Oslo Stock Exchange (OSE: NANO)

- Cash resources through 1H 2020

NHL: non-Hodgkin's lymphoma; 3L R/R FL – 3rd-line relapsed/refractory follicular lymphoma

NORDIC NANOVECTOR

Q1‘18 and post-period highlights

- Luigi Costa stepped down as CEO (April) – search for new CEO progressing
  - Tone Kvåle appointed Interim CEO and continues as CFO

- PARADIGME pivotal Phase 2b trial (Betalutin® in 3L R/R FL)
  - Start-up activities and patient screening underway, first patient expected 1H 2018
  - April update – timelines revised with first results targeted for 1H 2020 (previously 2H 2019)

- Humalutin® (^{177}Lu-conjugated chimeric anti-CD37 antibody in NHL)
  - Clinical development on hold

- Management team strengthened with dedicated IR and capital markets expertise
  - Malene Brondberg appointed as Vice President, IR and Corporate Communications

NORDIC NANOVECTOR

BETALUTIN® – BUILDING A COMPETITIVE PROFILE IN FL AND NHL

Nordic Nanovector ASA
Kjelsåsveien 168 B, 0884 Oslo, Norway
www.nordicnanovector.com
IR contact: IR@nordicnanovector.com

Single-agent Betalutin® is highly active in FL patients, especially in 3L

Response rates by subgroup and treatment arm

	ORR (CR + PR)	CR
All patients (n=62)	60%	24%
All FL patients (n=47)	64%	23%
Arm 1 (40/15) (n=25)	68%	28%
Arm 4 (100/20) (n=8)	50%	25%
FL with ≥2 prior therapies (3L FL) (n=32)	66%	25%

Median duration of response

	Median DoR
All iNHL patients (n=37)	13.3m
iNHL **CR** patients (n=15)	20.5m
All FL patients with 40/15 (n=17)	13.3m
FL **CR** patients with 40/15 (n=7)	22.9m

- Published data from the LYMRIT 37-01 Phase 1/2a trial*
- Population of primarily elderly, heavily pre-treated patients with advanced stage disease
- Patients with CR remain disease-free for a median of over 20.0 months with one-time Betalutin® administration

*Kolstad A, et al. Poster presented at ASH 2017. Abstract 2769; ORR – Overall response rate; CR – complete response; DoR – duration of response; iNHL – indolent NHL.

90% of evaluable patients had a decrease in tumour size

Best percentage change in tumour size from baseline by subtype (n=59)



*SPD = sum of the products of the diameters.
**Change in size of target lesion is beyond the scale for this figure (n=2).

Kolstad A, et al. Poster presented at ASH 2017. Abstract 2769.

NORDIC NANOVECTOR

Betalutin® is well-tolerated, with a manageable safety profile

Grade 3/4 TEAEs in ≥2 patients (n=64)

Adverse Event	n (%)[2]
Neutropenia[1]	35 (55%)
Thrombocytopenia[1]	32 (50%)
Leukopenia[1]	32 (50%)
Lymphopenia[1]	22 (34%)
Infections Urinary tract infection (1) Sepsis/neutropenic sepsis (2) Pharyngitis (1) Pneumonia (1)	5 (8%)
Lymphoma progression	3 (5%)
Serious Adverse Event (SAE)	
Thrombocytopenia	2 (3%)
Atrial fibrillation	2 (3%)
Lymphoma progression	2 (3%)

1. Including events reported as 'investigations'. 2. Two patients had not had hematologic recovery at the time of data cut-off.

- Overall, Betalutin® was well-tolerated, in particular considering the median age of enrolled patients
- Most common grade 3/4 TEAEs are reversible thrombocytopenia and neutropenia
- Low incidence of G3/4 infections (<10%)
- One report of MDS/CMML in a patient with prior alkylating agent exposure

Kolstad A, et al. Poster presented at ASH 2017. Abstract 2769.

NORDIC NANOVECTOR

Promising data support the potential of Betalutin®

- Clear need for new effective and well-tolerated therapies for patients who become refractory to rituximab, especially the elderly
- Single-agent Betalutin® shown to be well-tolerated and active in recurrent indolent NHL (LYMRIT 37-01 Phase 1/2a trial)
- With its promising clinical profile and ready-to-use formulation, Betalutin® has the potential to be a novel, safe and effective therapy for recurrent NHL
- Final analysis from LYMRIT 37-01 study (n=74) expected in 2H 2018, targeting ASH 2018 for read-out (December)



[1]No longer in clinical development for FL; [2] CAR-T; All agents are approved based on different phase results as mentioned along with asset; Results from different trials for comparison purpose only and NOT head to head studies.

NORDIC NANOVECTOR

Insight from pre-commercial research – defining optimal commercialisation strategy for success

- The value of Betalutin® as a new treatment option in NHL is clearly perceived
  - Efficacy is seen as a major strength
  - The combination of efficacy, manageable toxicity and simplicity makes Betalutin® truly appealing
  - It allows Betalutin® to enter an unsatisfied area of the market, and is well positioned to serve unmet needs among difficult-to-treat, refractory patients

- Clear strategies to maximise the clinical and commercial potential of Betalutin®
  - Pre-launch scientific engagement of key institutions and thought leaders on the benefits of the technology
  - Well-designed clinical development plan, aligned with health authority feedback
  - Robust market access and reimbursement programme
  - Optimised referral pathway
  - Streamlined manufacturing and distribution via a centralised logistics partner

PARADIGME: Seamless design for a robust dose selection aligned with regulatory feedback



- **Target is 130 patients at 80-85 sites in approximately 20 countries**
- **Primary endpoint**: Overall response rate (ORR)
- **Secondary endpoints**: Duration of response (DoR), Progression free survival (PFS), Overall survival (OS), Safety, Quality of life

- Two potential Betalutin® dosing regimens have emerged from LYMRIT 37-01 based on safety, efficacy and dosimetry data
- These will be compared with the goal to select the best Betalutin® dosing regimen
- Patient population: 3L FL patients who are refractory to anti-CD20 based therapy
- Seamless design approach based on data from the first part of the 37-01 study – more efficient than separate Phase 2 trial

NORDIC NANOVECTOR

PARADIGME status

- PARADIGME aims to recruit 130 3L R/R FL patients in 80-85 sites in 20 countries
  - First patient is expected to be dosed in 1H 2018

- As at May 29th, 2018, 23 clinical sites in 8 countries are open for enrolment
  - US sites expected to be open mid-year
  - Sites selected are clinical centres of excellence in the treatment of NHL and haematological malignancies

- Norway CTA update
  - As at May 29th Paradigme is fully approved in Norway

Our activities aimed at driving enrolment

- Key objectives:
  1. Complete site activation as fast as possible
  2. Start patient screening as soon as each site is activated
  3. Sustain the highest possible enrolment rate

- Key action items:
  - Fully leverage and reinforce Medical Science Liaison (MSL) organisation now deployed in Europe & USA
  - Deployment of study nurses/associates within high-traffic sites to help investigators identify patients
  - Partner with non-for-profit (i.e. Leukemia and Lymphoma Society) and other third-party organisations with experience in patient enrolment programmes
  - Meetings and regular webcasts with Investigators to maintain high level of attention on PARADIGME

PARADIGME timelines and expectations - revised in April

- Now targeting initial efficacy and safety data read-out for PARADIGME in 1H 2020 (previously 2H 2019)
- Targeting first regulatory filing in 2020
- Exploring ways to bring Betalutin® to patients quicker, e.g. via fast track, PRIME, breakthrough therapy designation (BTD)
- Financial resources are expected to be sufficient until data read-out from PARADIGME

Clinical development of Betalutin® in NHL: maximising its value potential

Targeted indication	Discovery	Preclinical	Phase 1	Phase 2	Phase 3
3L FL (PARADIGME)	Pivotal Phase 2b				
2L FL, combination w/ rituximab (Archer-1)	Phase 1b				
R/R DLBCL, SCT ineligible (LYMRIT 37-05)	Phase 1				
iNHL dosimetry (LYMRIT 37-02)	Phase 1				

- Priority focus on ongoing Betalutin® clinical development programmes
- Potential future opportunities in Betalutin® life-cycle management indications (R/R DLBCL conditioning, other NHL subtypes)
- Potential for other CD37-targeting therapies, including Humalutin® (a Phase 1-ready asset)

NORDIC NANOVECTOR

Archer-1: Betalutin® + rituximab (RTX) combination in 2L FL

- Explore Betalutin® + RTX combination in 2L NHL
  - RTX anti-CD20 immunotherapy is established standard of care in NHL
  - Approx. 8,980 (US) + 7,000 (EU-5) patients in 2014*
  - In preclinical model of NHL, Betalutin® + RTX inhibited tumour growth significantly and prolonged overall survival

- Phase 1b trial
  - A robust approach to generate safety, tolerability, pharmacokinetic and initial efficacy data in patients
  - CTA approved by NoMA, pending approval by REK
  - Start-up activities will commence upon regulatory approval
  - Expect first patient dosed in 2H 2018

*Decision Resources, 2015, Non-Hodgkin's Lymphoma

LYMRIT 37-05: Betalutin® in R/R DLBCL patients not eligible for stem cell transplantation (SCT)

- Explore Betalutin® single administration in DLBCL
  - DLBCL is an aggressive form of NHL and accounts for up to 43% of NHL
  - Estimated 14,000 patients (US, EU-5 and Japan)*
  - ~40% DLBCL patients relapse after 1L rituximab-chemotherapy and 60-70% relapsed patients fail or are unsuitable for subsequent high-dose chemotherapy followed by SCT
  - Few therapeutic options for patients NOT eligible for SCT

- On-going Phase 1 open label, single-administration, ascending-dose study
  - Objective to identify optimal dosing regimen for Phase 2 studies
  - Up to 24 patients planned to be enrolled in the US and EU
  - Started Q1 2017; first read-out targeted for 2H 2018

DLBCL: diffuse large B-cell lymphoma; *Decision Resources, 2015, Non-Hodgkin's Lymphoma

FINANCIALS AND SUMMARY

Nordic Nanovector ASA
Kjelsåsveien 168 B, 0884 Oslo, Norway
www.nordicnanovector.com
IR contact: IR@nordicnanovector.com

Majority of resources allocated to PARADIGME

Operating result



Operating expenses YTD March 2018



*Development costs: preclinical, clinical, medical affairs, regulatory and CMC activites

Solid cash position, expected to be sufficient to reach data read-out for PARADIGME in 1H 2020



* USD/NOK 8.24
** USD/NOK 7.97

NORDIC NANOVECTOR

Key company goals for 2018-2020

1H 2018	**Betalutin® in 3L FL**	PARADIGME: First patient dosed
2H 2018	**Betalutin® + rituximab in 2L FL**	Archer-1: First patient dosed*
2H 2018	**Betalutin® in R/R iNHL**	LYMRIT 37-01: Complete final analysis and first data read-out
2H 2018	**Betalutin® in DLBCL**	LYMRIT 37-05: Preliminary data read-out
1H 2020	**Betalutin® in 3L FL**	PARADIGME: Data read-out

* Pending approval from regulatory authorities

NORDIC NANOVECTOR

Financial calendar

Q1 2018 meeting (in Norwegian)	**May 31st, 2018**
Q2 2018 results	**August 22nd, 2018**
Q3 2018 results	**November 21st, 2018**
Q4 and FY 2018 results	**February 2019**

Dates subject to change. The time and location of the presentations will be announced in due time.

- A two-week quiet period has been introduced ahead of full year and quarterly results
- Please send Investor Relations enquiries to ir@nordicnanovector.com

NORDIC NANOVECTOR

Questions

Nordic Nanovector ASA
Kjelsåsveien 168 B, 0884 Oslo, Norway
www.nordicnanovector.com
IR contact: IR@nordicnanovector.com

Glossary

1L, 2L, 3L: First, second and third line of treatment

(A)SCT: (Autologous) stem cell transplant

ADC: Antibody-Drug-Conjugate

AHCP: Allied Healthcare Professional

AML: Acute Myeloid Leukemia

APAC: Asia-Pacific

ARC: Antibody-Radionuclide-Conjugate

ARCHER-1: Name of Nordic Nanovector's combination study; Betalutin® and rituximab

ASH: American Society of Hematology

Authorized User: Physician authorized to prescribe and administer a radiopharmaceutical drug

B-cell: A type of lymphocyte (white blood cell) in the humoral immunity of the body's adaptive immune system. Can be distinguished from other lymphocytes by the presence of a protein on the B-cell's outer surface known as a B cell receptor (BCR). This specialized receptor protein allows a B-cell to bind to a specific antigen**.**

CD20: B-lymphocyte antigen CD20 is an activated-glycosylated phosphoprotein expressed in the surface of all B-cells beginning at the pro-B phase and progressively increasing in concentration until maturity

CD37: B-lymphocyte antigen CD-37 is a protein, a member of the transmembrane 4 superfamily, also known as the tetraspanin superfamily of cell surface antigens

chHH1: Chimeric version of the HH1 antibody

CLL: Chronic Lymphocytic Leukemia

CR: Complete Response

DLBCL: Diffuse Large B-Cell Lymphoma

DoR: Duration of Response

EANM: European Association of Nuclear Medicine

EMA: European Medicines Agency

EMEA: Europe, Middle East, and Africa

FDA: Food and Drug Administration (US)

FDG PET/CT: Positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro- D-glucose integrated with computed tomography

FL: Follicular Lymphoma

GMP: Good Manufacturing Practice

Haem-Oncs: Haematologist-oncologist

HCP: Healthcare Professional

HH1: Lilotomab

Humalutin®: Chimeric anti-CD37 ARC

ICML: International Conference on Malignant Lymhoma

IND: Investigational New Drug

iNHL: Indolent non-Hodgkin Lymphoma

KI: Kinase Inhibitor

KOL: Key Opinion Leader

LCM: Life-cycle management

Lilotomab (llo): Betalutin® consists of the radionuclide lutetium-177 conjugated to the B-cell seeking anti-CD37 antibody lilotomab

Lu-177: Radionuclide lutetium-177

M.D: Medical Doctor

mAb: Monoclonal antibody

MBq: Megabecquerel (radioactivity measurement unit)

NORDIC NANOVECTOR

Glossary

MCL: Mantle Cell Lymphoma

Medicare: US government reimbursement program for insured elderly

MedOnc: Medical oncologist

MoA: Mechanism of Action

MSL: Medical science liaison

nASCT: Not eligible for autologous stem cell transplant

NCCN: National Comprehensive Cancer Network

NDA: New Drug Application

NET: Neuroendocrine tumour

NHL: Non-Hodgkin's Lymphoma

NM: Nuclear medicine specialist

NNV003: Chimeric anti-CD37 antibody developed by Nordic Nanovector

ODD: Orphan Drug Designation

ORR: Overall Response Rate (CR plus PR)

OS: Overall Survival

PARADIGME: name of Nordic Nanovector's pivotal Phase 2b study

PD: Progressive Disease

PFS: Progression Free Survival

Pi3K: Phosphoinositide 3-kinase; class of Pi3K inhibitors include idelalisib, copanlisib, duvelisib

PR: Partial Response

PRA: PRA Health Sciences, a clinical research and data analytics company

QoL: Quality of Life

R/R: Relapsed/refractory

R: Rituximab

RadOnc: Radiation oncologist

R-Benda/R-B/RB: Rituximab, bendamustine

R-Chemo: Combination treatment consisting of rituximab plus one (i.e., bendamustine, fludarabine) or more (i.e., CHOP, CVP) chemotherapy agents

R-CHOP: Rituximab, hydroxydaunorubicin (doxorubicin), oncovin (vincristine), prednisolone

R-CVP: Rituximab, cyclophosphamide, vincristine, prednisone

RIT: Radioimmunotherapy

R-Squared: Combination treatment consisting of rituximab plus lenalidomide

SAB: Scientific Advisory Board

Satetraxetan: International non-proprietary name for p-SCN-benzyl-DOTA

SD: Stable Disease

SPECT/CT: Single photon emission computed tomography (SPECT) integrated with computed tomography (CT)

T-cell: A type of lymphocyte (white blood cell) that plays a central role in cell-mediated immunity. Can be distinguished from other lymphocytes by the presence of a T-cell receptor (TCR) on the cell surface. They are called T-cells because they mature in the thymus

TKI: Tyrosine Kinase Inhibitor

TPP: Target Product Profile

TTR: Time to Recurrence

US: United States